A number of other research firms also recently commented on HLUYY. Zacks Investment Research downgraded H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Thursday, March 7th. JPMorgan Chase & Co. lowered H. Lundbeck A/S- from a “neutral” rating to an “underweight” rating in a report on Wednesday, January 2nd. Finally, Barclays upgraded H. Lundbeck A/S- from an “equal weight” rating to an “overweight” rating in a report on Friday, December 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $53.00.
HLUYY stock traded up $0.33 during midday trading on Thursday, hitting $43.01. The company’s stock had a trading volume of 1,318 shares, compared to its average volume of 3,780. H. Lundbeck A/S- has a 12 month low of $38.65 and a 12 month high of $73.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.43 and a quick ratio of 1.19. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 10.72 and a beta of -0.11.
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia.
Recommended Story: Bar Chart
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.